UNITY BIOTECHNOLOGY INC (UBX) Stock Price, Quote, News and Overview
NASDAQ:UBX - Nasdaq - US91381U2006 - Common Stock - Currency: USD
UBX Quote, Performance and Key Statistics
0.779
+0.01 (+1.18%)
The current stock price of UBX is 0.779 USD. In the past month the price decreased by -20.27%. In the past year, price decreased by -47.36%.
UBX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.84 | 324.18B | ||
| AMGN | AMGEN INC | 13.09 | 146.07B | ||
| GILD | GILEAD SCIENCES INC | 13.87 | 133.68B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 111.96B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.28 | 63.52B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 37.81B | ||
| ARGX | ARGENX SE - ADR | 100.1 | 35.88B | ||
| ONC | BEIGENE LTD-ADR | 6 | 26.10B | ||
| BNTX | BIONTECH SE-ADR | N/A | 23.72B | ||
| NTRA | NATERA INC | N/A | 20.94B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 19.20B | ||
| BIIB | BIOGEN INC | 7.95 | 18.43B |
Related stock screener links
About UBX
Company Profile
Unity Biotechnology, Inc. operates as a biotechnology company. The company is headquartered in South San Francisco, California and currently employs 16 full-time employees. The company went IPO on 2018-05-03. The firm is focused on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases. The company is targeting specific biological mechanisms implicated in diseases of aging. Its core therapeutic approach targets cellular senescence, and it is advancing senolytic programs primarily in ophthalmologic disorders. The company has other programs based on other biologies of aging to include an agonistic antibody to the Tie2 receptor and a Tie2/VEGF bispecific to treat vascular eye disease. UBX1325 is its advanced drug candidate for age-related diseases of the eye, including diabetic macular edema. UBX1325 is a potent small molecule inhibitor of BCL-xL. UBX2089, an α-Klotho hormone drug candidate, is being researched for multiple neurology indications.
Company Info
UNITY BIOTECHNOLOGY INC
285 East Grand Avenue
South San Francisco CALIFORNIA US
Employees: 16
Phone: 16504161192
UNITY BIOTECHNOLOGY INC / UBX FAQ
What is the stock price of UNITY BIOTECHNOLOGY INC today?
The current stock price of UBX is 0.779 USD. The price increased by 1.18% in the last trading session.
What is the ticker symbol for UNITY BIOTECHNOLOGY INC stock?
The exchange symbol of UNITY BIOTECHNOLOGY INC is UBX and it is listed on the Nasdaq exchange.
On which exchange is UBX stock listed?
UBX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for UNITY BIOTECHNOLOGY INC stock?
8 analysts have analysed UBX and the average price target is 5.1 USD. This implies a price increase of 554.69% is expected in the next year compared to the current price of 0.779. Check the UNITY BIOTECHNOLOGY INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is UNITY BIOTECHNOLOGY INC worth?
UNITY BIOTECHNOLOGY INC (UBX) has a market capitalization of 13.41M USD. This makes UBX a Nano Cap stock.
How many employees does UNITY BIOTECHNOLOGY INC have?
UNITY BIOTECHNOLOGY INC (UBX) currently has 16 employees.
What are the support and resistance levels for UNITY BIOTECHNOLOGY INC (UBX) stock?
UNITY BIOTECHNOLOGY INC (UBX) has a support level at 0.73 and a resistance level at 0.79. Check the full technical report for a detailed analysis of UBX support and resistance levels.
Is UNITY BIOTECHNOLOGY INC (UBX) expected to grow?
The Revenue of UNITY BIOTECHNOLOGY INC (UBX) is expected to decline by -100% in the next year. Check the estimates tab for more information on the UBX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy UNITY BIOTECHNOLOGY INC (UBX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of UBX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of UBX, evaluating the profitability, health, valuation and growth aspects
- UNITY BIOTECHNOLOGY INC (UBX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- UNITY BIOTECHNOLOGY INC (UBX) Sales and EPS estimates to see what analysts future expectations are.
- UNITY BIOTECHNOLOGY INC (UBX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- UNITY BIOTECHNOLOGY INC (UBX) Insider and Institutional Ownership to learn about the owners and their transactions.
- UNITY BIOTECHNOLOGY INC (UBX) Stock Chart to make your own analysis
- UNITY BIOTECHNOLOGY INC (UBX) Latest news and press-releases to stay up to date.
Does UNITY BIOTECHNOLOGY INC (UBX) stock pay dividends?
UBX does not pay a dividend.
When does UNITY BIOTECHNOLOGY INC (UBX) report earnings?
UNITY BIOTECHNOLOGY INC (UBX) will report earnings on 2025-08-04, after the market close.
What is the Price/Earnings (PE) ratio of UNITY BIOTECHNOLOGY INC (UBX)?
UNITY BIOTECHNOLOGY INC (UBX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.62).
What is the Short Interest ratio of UNITY BIOTECHNOLOGY INC (UBX) stock?
The outstanding short interest for UNITY BIOTECHNOLOGY INC (UBX) is 5.03% of its float. Check the ownership tab for more information on the UBX short interest.
UBX Technical Analysis
UBX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to UBX. While UBX seems to be doing ok healthwise, there are quite some concerns on its profitability.
UBX Financial Highlights
Over the last trailing twelve months UBX reported a non-GAAP Earnings per Share(EPS) of -1.62. The EPS increased by 23.94% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -69.01% | ||
| ROE | -400.22% | ||
| Debt/Equity | 0 |
UBX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to UBX. The Buy consensus is the average rating of analysts ratings from 8 analysts.
For the next year, analysts expect an EPS growth of 17.18% and a revenue growth -100% for UBX